Ectopic breast tissue carcinoma—a case report

Isabel Rodrigues1*, Nuno Pereira2, Ana Varelas3, Nuno Coimbra3, Conceição Leal3, Luís Lencastre4, Ana Ferreira5, Isabel Azevedo1, Helena Pereira1

European Journal of Medical Case Reports
Volume 4(5):161–165
© EJMCR. https://www.ejmcr.com/
Reprints and permissions: https://www.discoverpublish.com/
https://doi.org/10.24911/ejmcr/173-1571690517

ABSTRACT

Background: Ectopic breast cancer is a rare entity and an important diagnostic and treatment challenge.

Case Presentation: 46-year-old female with previous history of resection of ectopic axillary breast tissue who was referred to our Institution after a second resection following an increase in left axillary volume. Histology reported a ductal ectopic breast tissue carcinoma that invaded the deep layer of the dermis and was positive for estrogen and progesterone receptors and Human Epidermal growth factor Receptor-type 2. After being referred to our Institution, surgical margin re-excision and sentinel node biopsy were performed. The patient initiated hormone therapy and underwent adjuvant radiotherapy to the breast and axilla (50 Gy/25 fractions, in daily 2 Gy fractions with a 3D conformal radiation therapy technique) and boost with bolus to the axilla (to complete 60 Gy). She remains in follow-up, with no recurrence to date.

Conclusion: A high index of suspicion is required for the timely diagnosis of this rare condition. Since there are no specific guidelines, treatment remains a challenge.

Keywords: Breast cancer, breast ectopic carcinoma, breast ectopic tissue, axilla, adjuvant radiotherapy, case report.

Received: 23 October 2019 Accepted: 02 May 2020
Type of Article: CASE REPORT
Funding: None.

Declaration of conflicting interests: The authors declare that there is no conflict of interests regarding the publication of this case report.

Background

Ectopic breast cancer is defined as breast cancer that occurs in ectopic sites of breast tissue. It is a rare occurrence, accounting for 0.3%–0.6% of all breast cancer, and represents important challenges, both in diagnosis and clinical management. These difficulties may lead to a delay in diagnosis, which can have an impact in clinical outcome. Here, we report a case of ectopic breast cancer in a female patient who was referenced to our Institution.

Case Presentation

We report the case of a 46-year-old female patient, a factory worker who lives in a metropolitan area in the north of Portugal. She was referred to our Institution in May 2018 with the diagnosis of ectopic breast invasive carcinoma on the left axilla.

The patient had previously undergone a bilateral resection of ectopic axillary breast tissue for cosmesis in a private practice in 2012 and presented with no other personal relevant history. She was premenopausal, and her gynecological history included one healthy pregnancy 26 years prior. She mentioned swelling of the left axilla while breastfeeding her daughter, that subsided after applying pressure and massaging the axilla, which stimulated lactation through the nipple. She took oral birth control for 27 years. The patient had a sister who was diagnosed with invasive breast cancer 6 years prior, at the age of 50, and was alive and without recurrence.

After noticing an increase in volume in the previously excised left axillary tissue in April 2017, the patient underwent an ultrasound, and was again submitted to surgery outside our Institution, in which a skin patch with an 8 mm adjacent nodular lesion were removed.

Pathology reported a grade 2 invasive carcinoma of no special type [ductal no special type (NST)] in ectopic breast tissue, with accompanying ductal carcinoma in situ of intermediate nuclear grade. The neoplasia measured 0.9 cm and infiltrated the deep dermis and subcutaneous tissue, without lymphovascular permeation, with positive margins. The tumor cells were strongly immunoreactive for estrogen and progesterone receptors and inconclusive for Human Epidermal growth factor Receptor-type 2 (HER-2) [classified as negative after Fluorescence in situ hybridization (FISH)] (Figure 2). She was then referenced to our Hospital.

A bilateral breast MRI identified a heterogeneous 2.3 cm area on the upper inner quadrant of the right breast, also apparent in ultrasound, which was biopsied and was compatible with a radial scar.

After discussion in a dedicated group meeting, it was decided to perform a surgical margin re-excision
and sentinel node biopsy, and an excisional wire-guided biopsy of the right heterogeneous lesion, which took place in 24/08/2018, with no intra or post-operative complications. On the left side, histology showed no residual tumor and two non-involved sentinel lymph nodes. The lesion that was removed from the right breast was confirmed to be a radial scar.

The patient was staged as pT1bN0snM0 and, after discussion in a multidisciplinary meeting, was offered adjuvant radio and hormone therapy. Therefore, she initiated tamoxifen (200 mg/day) and goserelin in 26/09/2018. An adjuvant radiotherapy treatment was planned, to deliver 50 Gy in 25 fractions to the left breast and axilla, with 6 and 10 MV photons, employing a 3D conformal radiation therapy (3DCRT) technique, followed by a 10 Gy boost with bolus to the axilla (due to dermis invasion), with the same fractionation, energy, and technique (Figure 1, 3 and 4). The patient completed treatment in 30/11/2018, in 38 days, without interruptions, with grade 3 radiodermitis on the axilla. She remains in follow-up in our Institution, with no significant side effects or signs of recurrence (clinical or imagiologic) 1 year after adjuvant radiotherapy.

Discussion

Ectopic breast tissue (EBT) is rare (0.2%–6% of the population) [1] and develops as a consequence of the embryologic involution of the mammary ridge that forms across the milk line during the 4th week of gestation. This ectodermal structure slowly disappears during the 5th week, leaving behind the mammary sketch in the 4th intercostal space, a structure that will originate the adult mammary gland. Therefore, when present, ectopic breast tissue is located across the line that extends from the axilla (most frequently, in 58%–70% cases) to the inguinal region [2,3].

EBT is more common in Asian populations and appears to be associated with urological malformations [1]. In Europe, it can be found in 0.22% of the population [4]. The male-to-female ratio of the incidence of breast cancer in EBT seems to be higher than in orthotopic tissue (0.035 in the first and 0.01 in the latter). It seems to affect younger individuals than breast cancer in eutopic tissue but appears mainly in individuals older than 40 years [1]. Although most cases are sporadic, an autosomal dominant inheritance pattern with incomplete penetrance has been described in around 10% cases [4,5]. Around 200 ectopic

<table>
<thead>
<tr>
<th>CTV whole breast</th>
<th>V98 (with Boost)</th>
<th>88%</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTV boost</td>
<td>V98</td>
<td>96.6%</td>
</tr>
<tr>
<td>Boost skin</td>
<td>Median dose</td>
<td>54.1 Gy</td>
</tr>
<tr>
<td></td>
<td>Maximum dose</td>
<td>62.3 Gy</td>
</tr>
<tr>
<td>Left lung</td>
<td>V20</td>
<td>16%</td>
</tr>
<tr>
<td></td>
<td>Median dose</td>
<td>5 Gy</td>
</tr>
<tr>
<td>Heart</td>
<td>V20</td>
<td>5.5%</td>
</tr>
<tr>
<td></td>
<td>Median dose</td>
<td>3.1 Gy</td>
</tr>
<tr>
<td>Brachial plexus</td>
<td>Maximum dose</td>
<td>46.5 Gy</td>
</tr>
<tr>
<td></td>
<td>Median dose</td>
<td>2.9 Gy</td>
</tr>
<tr>
<td>Thyroid</td>
<td>Median dose</td>
<td>1 Gy</td>
</tr>
<tr>
<td></td>
<td>Maximum dose</td>
<td>3.7 Gy</td>
</tr>
<tr>
<td>Spinal cord</td>
<td>Maximum dose</td>
<td>2 Gy</td>
</tr>
</tbody>
</table>

Figure 1. Radiotherapy treatment plan characteristics (dose coverage and dose to the organs at risk) and dose-volume histogram.
breast carcinoma cases have been reported in the literature to date, most commonly in the axilla (also the most common location for EBT) [1,2].

Several systems for classification were postulated. The most used was published by Kajava [6] and divides EBT in eight categories, according to the supernumerary structures (Table 1). Copeland and Geschickter [7] proposed a different system, in which EBT was more simply classified as supernumerary breast (glandular tissue with an associated nipple or areola) or aberrant breast (glandular tissue without nipple or areola).

Most commonly, EBT becomes evident under hormonal stimulation, such as puberty or lactation, and can present with symptoms, such as tenderness, swelling, discomfort limiting arm movement, or secretion [1,3]. When in the axilla, the most relevant differential diagnosis is benign or malignant (primary or secondary) lymphadenopathy, sebaceous cyst, lipoma, lymphadenitis, and hidradenitis suppurativa [3,8].

There are no specific imagiologic features [2]. Fine needle aspiration, along with imagiology and clinical features, can be helpful in suggesting the presence of an ectopic breast carcinoma. However, in a retrospective study by Nihon-Yanagi et al. [2], an excisional biopsy or surgery specimen were needed to obtain a definitive diagnosis in most cases. Carcinoma in ectopic breast tissue must be differentiated from an axillary lymph node metastasis and eccrine carcinomas. The presence of adjacent normal breast ducts or lobules, the absence of lymph node tissue and the association with carcinoma in situ supports the diagnosis [3,9].
Histologically, most are ductal carcinomas (72%–79%), followed by lobular and medullary carcinomas (12%), and mucinous carcinomas (7.8%) in retrospective series by Marshall [10], Visconti [1], and Nihon-Yanagi [2]. In the latter, medullary, mucinous and apocrine carcinomas were more common in EBT than in orthotopic tissue [2]. Other histological types are reported to be rare [5].

Since there are no specific guidelines for the treatment of EBT carcinomas, they are usually treated in the same way as orthotopic breast tumors [5]. Local excision and axillary dissection is the procedure of choice for axillary EBT malignant lesions, since studies have shown that there is no evidence of ipsilateral breast involvement in radical mastectomy and autopsy specimens, even in patients with distant metastasis. Therefore, mastectomy does not seem to be necessary [2,11] and a multimodal approach is employed, with surgery, radiation, and systemic treatment on indication (chemo or hormonal therapy). Postoperative irradiation of the tumor site and regional lymph nodes is indicated [4]. In this case, we included the whole breast in the radiotherapy volume due to the history of lactation in the axillary tissue that drained through the nipple, probably indicating that the lymph drainage also followed the usual path, accompanying the ducts.

Given the rarity of EBT carcinoma, prognosis is difficult to establish. However, due to the frequent delay in diagnosis and clinical management of these cases, it seems to be worse than that of orthotopic breast carcinomas [5,10].

In our case, histology of the surgical specimen established diagnosis, which allowed for a timely re-intervention and subsequent adjuvant treatments. This was eased by the patient’s medical history, which comprised a previous surgery for removal of axillary EBT for aesthetic reasons (which was not complete). The patient will remain in follow-up in our Institution.

Conclusion
A high index of suspicion is required for the timely diagnosis of this rare condition. Since there are no specific guidelines, treatment remains as a challenge.

Table 1. Kajava system for classification of EBT.

| I | Complete supernumery breast (polymastia—nipple, areola and glandular tissue) |
| II | Supernumery nipple and glandular tissue (no areola) |
| III | Supernumery areola and glandular tissue (no nipple) |
| IV | Glandular tissue only |
| V | Supernumery areola and nipple (pseudomamma—no glandular tissue, fat only) |
| VI | Supernumery nipple only (polythelia) |
| VII | Supernumery areola only (polythelia areolaris) |
| VIII | Patch of hair only (polythelia pilosa) |

What is new?
Ectopic Breast Carcinoma is rare, and diagnosis is often delayed. Since there are no specific guidelines available, this case report focuses on adjuvant radiotherapy, and summarizes the available literature on this uncommon entity.

List of Abbreviations
- 3DCRT 3D conformal radiation therapy
- EBT ectopic breast tissue
- HER2 Human Epidermal growth factor Receptor-type 2
- NST no special type
- FISH Fluorescence in situ hybridization

Consent for publication
Written informed consent was taken from the patient.

Ethical approval
Ethical approval was obtained from the Institutional ethics boards.

Author details
Isabel Rodrigues1, Nuno Pereira2, Ana Varelas3, Nuno Coimbra3, Conceição Leal3, Luís Lencastre4, Ana Ferreira5, Isabel Azevedo1, Helena Pereira5
1. External Radiotherapy Department, Instituto Portugues de Oncologia Francisco Gentil do Porto, Portugal
2. Medical Physics Department, Instituto Portugues de Oncologia Francisco Gentil do Porto, Portugal
3. Pathological Anatomy Department, Instituto Portugues de Oncologia Francisco Gentil do Porto, Portugal
4. Surgical Oncology Department, Instituto Português de Oncologia Francisco Gentil do Porto, Portugal
5. Medical Oncology Department, Instituto Português de Oncologia Francisco Gentil do Porto, Portugal

References


Summary of the case

<table>
<thead>
<tr>
<th></th>
<th>Patient (gender, age)</th>
<th>Final diagnosis</th>
<th>Symptoms</th>
<th>Medications</th>
<th>Clinical procedure</th>
<th>Specialty</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Female, 46-year old</td>
<td>Ectopic breast tissue carcinoma</td>
<td>Increase in volume in the axilla</td>
<td>Adjuvant tamoxifen</td>
<td>Adjuvant radiotherapy</td>
<td>Radiation Oncology</td>
</tr>
</tbody>
</table>